Beam Therapeutics Inc. (BEAM) /
The cash flow of Beam Therapeutics Inc. over the past 7 years
Chart Beam Therapeutics Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2019–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Beam Therapeutics Inc.'s operating cash flow was -$345.1M and its capital expenditures $14.95M, leaving free cash flow of -$360.05M. Free cash flow was below zero in all 7 years shown. It ranged from -$360.05M in fiscal 2025 to -$26.42M in fiscal 2022. Capital expenditures were highest in fiscal 2022, at $48.95M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$345.1M | $14.95M | -$360.05M |
| 2024ended Dec 31, 2024 | -$347.25M | $8.95M | -$356.19M |
| 2023ended Dec 31, 2023 | -$149.19M | $33.73M | -$182.93M |
| 2022ended Dec 31, 2022 | $22.53M | $48.95M | -$26.42M |
| 2021ended Dec 31, 2021 | -$66.27M | $46.81M | -$113.08M |
| 2020ended Dec 31, 2020 | -$95.74M | $16.36M | -$112.1M |
| 2019ended Dec 31, 2019 | -$72M | $12.52M | -$84.52M |
Fiscal years as Beam Therapeutics Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Beam Therapeutics Inc.
- The revenue of Beam Therapeutics Inc.
- The profitability of Beam Therapeutics Inc.
- The debt of Beam Therapeutics Inc.
- All of Beam Therapeutics Inc.'s financials, charted
Companies of a similar size
- CLSKCleanSpark, Inc.
- ADEAADEIA INC.
- QSQUANTUMSCAPE CORPORATION
- BHFBrighthouse Financial, Inc.
- UPSTUpstart Holdings, Inc.
Not investment advice. This page shows what Beam Therapeutics Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.